Risk factors for acute myocardial infarction and medication prescription for secondary prevention
DOI:
https://doi.org/10.51481/amc.v47i1.171Keywords:
infarto agudo de miocardio, prevención secundaria, colesterol, aspirina, atenolol, enalaprilAbstract
Objective:To describe some factors of coronary riskpresent in patients who survive a first acute myocardialinfartion and the pharmacological treatment prescribed forsecondary prevention.
Methods:Observational, cross sectional and descriptivepilot study, information was obtained from the charts of 50patients seen at 3 national hospitals.
Results:42 males and 8 women, age 63 ± 15 years, weight67 ± 12 kg, Body Mass Index = 26.1 ± 2.1 kg/m2, 38%hypertensive, 22% diabetic (n = 8 smokers patients withdiabetes+hypertension) and 34% smokers. Total cholesterollevels: 191 ± 45.7 mg/dL, cholesterol-LDL= 112 ± 33.8mg/dL and cholesterol-HDL: 39.4 ± 8.26 mg/dL. Thepatients were prescribed: 92% antithrombotics drugs (pre-dominated aspirin), 92% statins, 78 % beta-blockers(atenolol or carvedilol), 70% enalapril or losartan and 48%nitrates.
Conclusions:this preliminary study indicateds that coro-nary disease appears in young adult, it's most frequent inmales and showeds modifiable factors of risks.Antithrombotics drugs, beta-blockers and statins are mostfrequently.
Downloads
References
Hutton I (Ed.): Secondary prevention of coronary heart disease fol-lowing myocardial infarction. Scottish Intercollegiate GuidelinesNetwork. SIGN publication N° 41. Edinburgh: Royal College ofPhysicians, 2000.
Collier J (Ed.): Tratamiento del infarto agudo del miocardio. DrugTher Bull 2000, 38: 13-16 (ed española).
Mehta RH, Eagle KA. Secondary prevention in acute myocardialinfarction. BMJ 1998, 316: 838-42.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysisof randomised trials of antiplatelet therapy for prevention of death,myocardial infarction and stroke in high risk patients. BMJ 2002;324: 71-86.
Freemantle N, Cleland J, Young P, Mason J, Harrison J: Beta block-ade after myocardial infarction: systematic review and meta-regres-sion analysis. BMJ 1999, 318: 1730-7.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.: Effectsof an angiotensin-converting-enzime inhibitor, ramipril, on cardio-vascular events in high -risk patients. The Heart OutcomesPrevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-53.
Heart protection study collaborative group. MCR/BHF HeartProtection Study of cholesterol lowering with simvastatin in 20,536high- risk individuals: a randomised placebo-controlled trial. Lancet2002, 360: 7-22.
Lacy Ch.F., Armstrong L.L., Goldman M.P., Lance L.L.: Obesitytreatment guidelines for adults. Summary of clinical practice guide-lines National Heart, Lung and Blood Institute. In: Drug InformationHandbook, 11th edition. Ontario: AphA, Lexi-Comp Inc, 2003.
Smith SC, Blair SN, Bonow RO, Brass LM, Cequeira MD, Dracup K,et al.: AHA/ACC guidelines for preventing heart attack and death inpatients with atherosclerotic cardiovascular disease: 2000 update. JAm Coll Cardiol 2001; 38: 1581-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
